Answers are grounded in this paper and cite their sources.
People with HIV (PWH) show heterogeneous ageing trajectories shaped by both HIV-related and non-HIV factors. DNA methylation (DNAm)-derived ageing biomarkers are increasingly used in HIV research, but their clinical meaning remains uncertain. This Review considers how such findings should be interpreted in relation to clinically relevant vulnerability. Cross-sectional associations should be distinguished from longitudinal prediction, and any added predictive value should be tested against established clinical measures. Interpretation also depends on what each DNAm measure was trained to capture and on the clinical setting in which it is studied. We examine evidence relating DNAm biomarkers to frailty, physical function, physiologic risk, and clinical outcomes, with particular attention to immune status and treatment history. Current evidence supports their use as research tools rather than as individual diagnostic tests or guides to treatment.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: